Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-553-2 | CAS number: 84-69-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP, guideline study, animal experimental study with minor restrictions, fully adequate for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 995
Materials and methods
- Principles of method if other than guideline:
- Subchronic toxicity study with perinatal exposure in which pups from dams exposed during pregnacy and lactation were treated for an additional 13 wk post-weaning
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Dibutyl phthalate
- EC Number:
- 201-557-4
- EC Name:
- Dibutyl phthalate
- Cas Number:
- 84-74-2
- IUPAC Name:
- dibutyl phthalate
- Details on test material:
- Dibutyl phthalate (Lot L-121 1-83) was obtained from Chem Central (Kansas City, MO). Initia l
identity and purity analysesconformed it to be 9.8%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
- Details on oral exposure:
- The exposure concentrations selected for the 13-week studies with no perinatal exposure were based on the results for rat dams used in the MPE determination study; in the 13-week studies, groups of 10 rats per sex were administered 0, 2,500, 5,000, 10,000, 20,000, or 40,000 ppm dibutyl phthalate and groups of 10 mice per sex were administered
0, 2500, 5,000, 10,000, 20,000 or 40.000 ppm dibutyl phthalate in feed 7 days a week for 13 weeks.
The dose levels equated to
0 , 176, 359, 720, 1540 and 2964 mg/kg/day for males and
0, 178, 356, 712, 1413 and 2943 mg/kg/day for females - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability studies performed by MRI on Lot C100682 on a gas chromatographic system with an FID indicated that dibutyl phthalate is stable as a bulk chemical for 2 weeks when stored protected from light at temperatures up to 60 C. Throughout the studies, dibutyl phthalate was stored at room temperature; periodic reanalyses performed by the study laboratory with infrared spectroscopy, gas chromatography, and ester hydrolysis titration indicated no decomposition of the bulk chemical.
- Duration of treatment / exposure:
- 13 weeks 7 days/ week
- Frequency of treatment:
- Continous
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 2,500, 5,000, 10,000, 20,000, or 40,000 ppm dibutyl phthalate
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
Equivalent to 0, 176, 359, 720, 1,540 and 2,964 mg/kg bwt for males
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
Equivalent to 0, 178, 356, 712, 1,413 and 2,943 mg/kg bwt for females
Basis:
nominal in diet
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, plain diet
- Positive control:
- None
Examinations
- Sacrifice and pathology:
- Complete necropsies were performed on all animals. The following organs were weighed: heart, right kidney, liver, lungs, right testis, and thymus.
Histopathologic evaluations were performed on all animals in the control and highest exposure groups. The tissues routinely examined were the same as in the 13 weeks study with perinatal exposure. Gross lesions of rats and mice in all our exposure groups are examined tissues examined in the lower exposure groups include the liver, and the testes of ratsand the liver of mice - Other examinations:
- haematologyand clinical chemistry evaluation is evaluations were done at the end of the studies. Haematology and clinical chemistry parameters evaluated was the same as in the other 13 weeks studies with perinatal exposure.
Zinc and testosterone levels were measured in the sera and testes of all male rats. Sperm motility and vaginal cytology were performed in rats, up to the 20,000 ppm groups.
the livers of five male and five female rats a group were analysed for hepatic paroxysm proliferation and liver enlargement. By monitoring increases in peroxisomal parmitol-CoA activity andliver weight.
Results and discussion
Results of examinations
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Details on results:
- Growth: statistically significantly decreased in both sexes at 20000 ppm BNP and above, and in males only at 10000 ppm.
Food intake: decreased for males and females at 40000 ppm in the diet (all animals were emaciated).
Haematology: statistically significantly decreased haemoglobin values and erythrocyte counts at 5000 ppm and above (males only); haematocrit values statistically significantly decreased at 20000 and 40000 ppm (males only); statistically significantly increased platelet count at 5000 ppm and above (males only); statistically significantly increased nucleated erythrocytes at 40000 ppm (both sexes).
Clinical chemistry: statistically significantly decreased cholesterol at 20000 and 40000 ppm (both sexes); statistically significantly, dose-related, decreased triglyceride levels in all treated males and in females at 10000 ppm and above; statistically significantly increased serum alkaline phosphatase in males at 20000 and 40000 ppm, and in females at 10000 and above; significantly increased serum bile acid concentration in males at 20000 and 40000 ppm and in females at 5000 ppm and above; dose-related, increased PCoA activity (cyanide-insensitive palmitoyl-CoA oxidase activity, an indicator of peroxisome proliferation) at 5000 ppm and above in both sexes.
Organ weights: statistically significantly increased relative liver and kidney weights in males at 5000 ppm and above and in females at 10000 and above; statistically significantly decreased testicular weights at 20000 and 40000 ppm.
Histopathology:
- liver: hepatocellular cytoplasmic alterations, consistent with glycogen depletion, at 10000 ppm and above (both sexes); fine, eosinophilic granules present at 40000 ppm, with an increased number of peroxisomes visible using electron microscopy; lipofuscin accumulation (both sexes) at 10000 ppm and above.
- testis: dose-related degeneration of germinal epithelium at 10000 ppm and above with almost complete loss of germinal epithelium at 40000 ppm;
Other:
- statistically significantly decreased testicular zinc and serum testosterone concentrations at 20000 and 40000 ppm; statistically significantly lower serum zinc at 40000 ppm.
- statistically significantly reductions in spermatid heads/testis and per g of testis, epididymal spermatozoal motility, and the number of epididymal spermatozoa per g epididymis at 20000 ppm and above.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 177 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Remarks:
- in the diet
- Sex:
- male/female
- Basis for effect level:
- other: based on alterations in haematological parameters, serum chemistry and organ weights at 356-359 mg/kg bw/d
- Dose descriptor:
- NOAEL
- Effect level:
- 359 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Remarks:
- in the diet
- Sex:
- male
- Basis for effect level:
- other: degeneration of germinal epithelium at 720 mg/kg bw/d
- Dose descriptor:
- NOAEL
- Effect level:
- 177 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Remarks:
- in the diet
- Sex:
- male/female
- Basis for effect level:
- other: peroxisome proliferation-related changes in liver (increased PCoA activity) at 356-359 mg/kg bw/d
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In a well conducted 13 week feeding study in rats with dIbutylphthalate, principle effects were seen in the liver and testis with an overall NOAEL og 177 mg/kg bw/d.
- Executive summary:
The subchronic oral toxicity of dibutyl phthalate was investigated in groups of F344/N rats (n = 10/sex) fed diets containing 0, 2500, 5000, 10000, 20000 or 40000 ppm DBP. This was equivalent to approx. 0, 176, 359, 720, 1,540 or 2,964 mg/kg bw for males and approx. 0, 178,356, 712, 1,413 or 2,943 mg/kg bw for females. The overall NOAEL from this study was 2500 ppm DIB in the diet (equivalent to 177 mg/kg bw/d, both sexes) based on alterations in haematological, serum chemistry and organ weight values at 5000 ppm. The NOAEL for effects on testis (degeneration of germinal epithelium) was 5000 ppm (359 mg/kg bw/d). The NOAEL for peroxysome prolifearation-related changes (increased PCoA activity) was 2500 ppm in both sexes (177 mg/kg bw/d).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.